Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Laurie Keating. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Laurie Keating har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:PEPG / PepGen Inc. | Director | 4 166 |
US:IMRX / Immuneering Corporation | Director | 14 000 |
US:IMGO / Imago BioSciences Inc | Director | 23 809 |
US:ALNY / Alnylam Pharmaceuticals, Inc. | EVP, Chief Legal Officer | 1 124 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Laurie Keating. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp IMRX / Immuneering Corporation - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i IMRX / Immuneering Corporation. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel IMRX / Immuneering Corporation - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i IMRX / Immuneering Corporation. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internkjøp PEPG / PepGen Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i IMRX / Immuneering Corporation. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-06 | PEPG | KEATING LAURIE | 4 166 | 12,0000 | 4 166 | 12,0000 | 49 992 | 283 | 17.7000 | 23 746 | 47,50 |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel PEPG / PepGen Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i IMRX / Immuneering Corporation. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Laurie Keating som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-19 |
|
4 | PEPG |
PepGen Inc.
Common Stock |
P - Purchase | 4 166 | 4 166 | 12,00 | 49 992 | 49 992 | ||
2022-05-17 |
|
4 | IMRX |
Immuneering Corp
Class A Common Stock |
P - Purchase | 7 000 | 14 000 | 100,00 | 5,00 | 35 000 | 70 000 | |
2022-05-10 |
|
4 | PEPG |
PepGen Inc.
Stock Option (Right to Buy) |
A - Award | 5 833 | 5 833 | |||||
2021-11-19 |
|
4 | IMGO |
Imago BioSciences, Inc.
Stock Option (Right to Buy) |
A - Award | 23 809 | 23 809 | |||||
2021-08-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −7 876 | 1 124 | −87,51 | |||
2021-08-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
M - Exercise | X | −2 124 | 11 876 | −15,17 | |||
2021-08-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 000 | 5 132 | −66,09 | 188,95 | −1 889 500 | 969 691 |
2021-08-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 124 | 15 132 | 16,33 | 88,95 | 188 930 | 1 345 991 |
2021-08-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 7 876 | 13 008 | 153,47 | 88,95 | 700 570 | 1 157 062 |
2021-08-04 |
|
4 | IMRX |
Immuneering Corp
Class A Common Stock |
P - Purchase | 7 000 | 7 000 | 15,00 | 105 000 | 105 000 | ||
2021-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −5 000 | 9 000 | −35,71 | |||
2021-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −1 812 | 17 188 | −9,54 | |||
2021-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 000 | 5 132 | −49,35 | 178,95 | −894 750 | 918 371 |
2021-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 812 | 10 132 | −15,17 | 179,00 | −324 348 | 1 813 628 |
2021-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 5 000 | 11 944 | 72,00 | 88,95 | 444 750 | 1 062 419 |
2021-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 812 | 6 944 | 35,31 | 85,00 | 154 020 | 590 240 |
2021-06-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 734 | 5 132 | −25,25 | 154,00 | −267 036 | 790 328 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −75 | 6 866 | −1,08 | 134,42 | −10 081 | 922 916 | |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −2 014 | 6 941 | −22,49 | 131,75 | −265 344 | 914 477 | |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 4 518 | 8 955 | 101,83 | ||||
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 17 846 | 17 846 | |||||
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −106 | 4 437 | −2,33 | 153,54 | −16 275 | 681 257 | |
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −1 857 | 4 543 | −29,02 | 156,00 | −289 692 | 708 708 | |
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 4 584 | 10 000 | 84,64 | ||||
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 4 166 | 6 400 | 186,48 | ||||
2021-01-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 000 | 19 000 | −24,00 | |||
2021-01-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −3 027 | 2 164 | −58,31 | |||
2021-01-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 027 | 2 234 | −31,49 | 174,00 | −178 698 | 388 716 |
2021-01-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 000 | 3 261 | −47,92 | 170,00 | −510 000 | 554 370 |
2021-01-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 000 | 6 261 | −44,40 | 169,00 | −845 000 | 1 058 109 |
2021-01-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 000 | 11 261 | 114,05 | 85,00 | 510 000 | 957 185 |
2021-01-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 027 | 5 261 | 135,50 | 77,40 | 234 290 | 407 201 |
2021-01-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −13 000 | 5 191 | −71,46 | |||
2021-01-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −1 941 | 2 370 | −45,02 | |||
2021-01-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 000 | 2 234 | −57,32 | 165,00 | −495 000 | 368 610 |
2021-01-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 941 | 5 234 | −69,53 | 159,00 | −1 898 619 | 832 206 |
2021-01-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 13 000 | 17 175 | 311,38 | 77,40 | 1 006 200 | 1 329 345 |
2021-01-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 941 | 4 175 | 86,88 | 42,22 | 81 949 | 176 268 |
2021-01-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −758 | 2 234 | −25,33 | 154,00 | −116 732 | 344 036 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 250 | 7 500 | −45,45 | |||
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −23 809 | 18 191 | −56,69 | |||
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −1 941 | 4 311 | −31,05 | |||
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
M - Exercise | X | −3 750 | 5 416 | −40,91 | |||
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 530 | 2 992 | −76,11 | 162,24 | −1 546 147 | 485 422 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −15 618 | 12 522 | −55,50 | 161,32 | −2 519 496 | 2 020 049 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −14 236 | 28 140 | −33,59 | 160,52 | −2 285 163 | 4 517 033 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 061 | 42 376 | −2,44 | 159,22 | −168 932 | 6 747 107 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 323 | 43 437 | −5,08 | 158,27 | −367 661 | 6 874 774 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 482 | 45 760 | −8,92 | 157,16 | −704 391 | 7 191 642 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 50 242 | 14,21 | 119,13 | 744 562 | 5 985 329 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 750 | 43 992 | 9,32 | 119,13 | 446 738 | 5 240 767 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 23 809 | 40 242 | 144,89 | 77,40 | 1 842 817 | 3 114 731 |
2020-07-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 941 | 16 433 | 13,39 | 42,22 | 81 949 | 693 801 |
2020-04-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 42 000 | −19,23 | |||
2020-04-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 000 | 14 492 | −40,83 | 139,00 | −1 390 000 | 2 014 388 |
2020-04-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 10 000 | 24 492 | 69,00 | 77,40 | 774 000 | 1 895 681 |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −75 | 14 492 | −0,51 | 105,63 | −7 922 | 1 530 790 | |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −1 858 | 14 567 | −11,31 | 104,75 | −194 626 | 1 525 893 | |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 4 167 | 16 425 | 33,99 | ||||
2020-02-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 24 554 | 24 554 | |||||
2020-02-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 52 000 | −16,13 | |||
2020-02-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 000 | 12 258 | −44,93 | 129,00 | −1 290 000 | 1 581 282 |
2020-02-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 10 000 | 22 258 | 81,58 | 77,40 | 774 000 | 1 722 769 |
2020-02-12 |
|
4/A | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 663 | 12 258 | 42,62 | 77,40 | 283 516 | 948 769 |
2020-01-31 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 337 | 62 000 | −9,27 | |||
2020-01-31 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −6 337 | 8 595 | −42,44 | 119,00 | −754 103 | 1 022 805 | |
2020-01-31 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 337 | 14 932 | 73,73 | 77,40 | 490 484 | 1 155 737 |
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −3 663 | 68 337 | −5,09 | |||
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −9 374 | 6 252 | −59,99 | |||
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
M - Exercise | X | −25 000 | 0 | −100,00 | |||
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −190 | 8 595 | −2,16 | 120,21 | −22 840 | 1 033 205 |
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 667 | 8 785 | −43,15 | 119,53 | −796 907 | 1 050 071 |
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −13 084 | 15 452 | −45,85 | 118,61 | −1 551 893 | 1 832 762 |
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 100 | 28 536 | −12,56 | 117,67 | −482 447 | 3 357 831 |
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −13 631 | 32 636 | −29,46 | 116,43 | −1 587 057 | 3 799 809 |
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 365 | 46 267 | −6,78 | 115,55 | −388 826 | 5 346 152 |
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 25 000 | 49 632 | 101,49 | 42,22 | 1 055 500 | 2 095 463 |
2020-01-29 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 9 374 | 24 632 | 61,44 | 42,22 | 395 770 | 1 039 963 |
2019-12-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 4 583 | 9 166 | 100,00 | ||||
2019-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 4 583 | 4 583 | |||||
2019-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 10 | 434 | 2,36 | ||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 25 000 | 33,33 | ||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 3 500 | 14 000 | 33,33 | ||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 49 | 424 | 13,07 | ||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 18 750 | 50,00 | ||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 41 | 375 | 12,28 | ||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 14 | 334 | 4,38 | ||||
2019-03-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2018-09-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 12 500 | 100,00 | ||||
2018-09-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 3 500 | 10 500 | 50,00 | ||||
2018-08-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 3 500 | 7 000 | 100,00 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −605 | 15 258 | −3,81 | 90,95 | −55 025 | 1 387 715 | |
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 1 363 | 15 863 | 9,40 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 1 984 | 5 958 | 49,92 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 32 | 320 | 11,11 | ||||
2018-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −1 563 | 15 626 | −9,09 | |||
2018-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 563 | 14 500 | −9,73 | 105,04 | −164 178 | 1 523 080 |
2018-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 563 | 16 063 | 10,78 | 42,22 | 65 990 | 678 180 |
2018-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 31 | 288 | 12,06 | ||||
2018-03-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −1 562 | 17 189 | −8,33 | |||
2018-03-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −300 | 14 500 | −2,03 | 152,79 | −45 837 | 2 215 455 |
2018-03-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −200 | 14 800 | −1,33 | 151,48 | −30 296 | 2 241 904 |
2018-03-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −500 | 15 000 | −3,23 | 149,97 | −74 985 | 2 249 550 |
2018-03-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −462 | 15 500 | −2,89 | 147,79 | −68 279 | 2 290 745 |
2018-03-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −100 | 15 962 | −0,62 | 146,36 | −14 636 | 2 336 198 |
2018-03-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 562 | 16 062 | 10,77 | 42,22 | 65 948 | 678 138 |
2018-03-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 72 000 | −12,20 | |||
2018-03-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 000 | 14 500 | −40,82 | 150,00 | −1 500 000 | 2 175 000 |
2018-03-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 10 000 | 24 500 | 68,97 | 77,40 | 774 000 | 1 896 300 |
2018-03-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −10 000 | 82 000 | −10,87 | |||
2018-03-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 000 | 14 500 | −40,82 | 140,00 | −1 400 000 | 2 030 000 |
2018-03-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 10 000 | 24 500 | 68,97 | 77,40 | 774 000 | 1 896 300 |
2018-03-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 13 750 | 13 750 | |||||
2018-01-03 |
|
4 | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | −3 000 | 92 000 | −3,16 | ||||
2018-01-03 |
|
4 | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 3 000 | 14 500 | 26,09 | 77,40 | 232 200 | 1 122 300 | |
2017-12-21 |
|
4 | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 249 | 18 751 | −25,00 | |||
2017-12-21 |
|
4 | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2016 (right to buy) |
A - Award | 6 250 | 6 250 | |||||
2017-12-21 |
|
4 | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −300 | 11 500 | −2,54 | 122,53 | −36 760 | 1 409 133 |
2017-12-21 |
|
4 | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 900 | 11 800 | −13,87 | 121,67 | −231 182 | 1 435 761 |
2017-12-21 |
|
4 | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 049 | 13 700 | −22,81 | 120,88 | −489 456 | 1 656 101 |
2017-12-21 |
|
4 | ALKS |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 249 | 17 749 | 54,34 | 42,22 | 263 833 | 749 363 |
2017-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −30 000 | 95 000 | −24,00 | |||
2017-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 199 | 11 500 | −35,02 | 137,29 | −851 061 | 1 578 835 |
2017-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 700 | 17 699 | −35,40 | 136,50 | −1 324 050 | 2 415 914 |
2017-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −7 500 | 27 399 | −21,49 | 135,56 | −1 016 700 | 3 714 208 |
2017-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 801 | 34 899 | −9,82 | 134,59 | −511 577 | 4 697 056 |
2017-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 800 | 38 700 | −6,75 | 133,37 | −373 436 | 5 161 419 |
2017-12-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 30 000 | 41 500 | 260,87 | 77,40 | 2 322 000 | 3 212 100 |
2017-11-08 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 3 500 | 3 500 | |||||
2017-07-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 1 987 | 3 974 | 100,00 | ||||
2017-05-31 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 11 500 | 11 500 | 65,35 | 751 502 | 751 502 | ||
2016-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2016-02-03 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 1 987 | 1 987 | |||||
2015-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 14 000 | 14 000 | |||||
2015-05-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
A - Award | 5 959 | 5 959 |